Page last updated: 2024-12-05

4-anisidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Anisidine, also known as p-anisidine, is an organic compound with the formula CH3OC6H4NH2. It is a colorless to pale yellow solid, with a characteristic aromatic odor. It is used in the production of dyes, pharmaceuticals, and other organic chemicals. 4-Anisidine is a versatile building block for organic synthesis due to its reactivity. It is often used in the production of azo dyes, which are used to color textiles and other materials. 4-Anisidine can also be used to synthesize other aromatic compounds, such as pharmaceuticals and agricultural chemicals. It is important to note that 4-Anisidine is a known human carcinogen and should be handled with caution. Researchers study 4-Anisidine to understand its potential health risks and to develop methods for its safe handling and disposal. '

4-anisidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

p-anisidine : A substituted aniline that is aniline in which the hydrogen para to the amino group has been replaced by a methoxy group. It is used as a reagent for the detection of oxidation products such as aldehydes and ketones in fats and oils. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7732
CHEMBL ID295652
CHEBI ID82388
SCHEMBL ID5097
MeSH IDM0061902

Synonyms (103)

Synonym
HMS1757G11
AC-565
BIDD:GT0008
(4-methoxyphenyl)-amine
4-methoxybenzeneamine
benzenamine, 4-methoxy-
nsc7921
anisole, p-amino-
p-aminoanisole
p-anisidine
4-anisidine
p-methoxyaniline
aniline, p-methoxy-
4-aminoanisole
4-methoxybenzenamine
1-amino-4-methoxybenzene
4-methoxyaniline
nsc-7921
p-methoxyphenylamine
wln: zr do1
p-anisylamine
104-94-9
AC-907/25014180
4-methoxy-aniline
inchi=1/c7h9no/c1-9-7-4-2-6(8)3-5-7/h2-5h,8h2,1h
NCGC00091136-01
hsdb 1603
aniline, 4-methoxy-
p-dianisidine
4-methoxy-1-aminobenzene
ai3-02392
einecs 203-254-2
ccris 917
nsc 7921
p-anisidine, >=99%
para-anisidine
STK258849
A0802
A0487
4-methoxy-phenylamine
CHEMBL295652
chebi:82388 ,
AKOS000100571
FT-0693135
FT-0650502
NCGC00091136-04
NCGC00091136-03
anisidine
C19326
dtxsid7024532 ,
dtxcid104532
NCGC00257099-01
cas-104-94-9
tox21_303039
tox21_202437
NCGC00259986-01
29191-52-4
575917snr4 ,
unii-575917snr4
4-methoxyphenylamine
BP-12035
p-anisidine [hsdb]
anisidine, p-
AM84313
SCHEMBL5097
para anisidine
4-amino-1-methoxybenzene
4methoxyaniline
4methoxy-phenylamine
4-(methyloxy)aniline
4-methoxy-phenyl amine
4-methoxy phenyl amine
4-amino-anisole
paraanisidine
rho-anisidine
para-methoxyaniline
p-methoxy phenylamine
(4-methoxyphenyl)amine
p-methoxy aniline
p-anisidin
4-methoxy aniline
Q-200438
STR00220
Z56938150
4-methoxy-benzenamine
F2190-0441
mfcd00007864
1820684-56-7
4-(methoxy-d3)aniline hydrochloride
1-methoxy-4-amino-benzen (p-anisidin)
1-methoxy-4-amino-benzene / p-anisidine
p-methoxy-aniline
beta -anisidine
p-amino-anisole
A937237
CS-0015840
Q3333299
BCP26755
4-methoxyaniline--d4
EN300-17444
para-methoxy aniline
p-methoxyphenyl amine
O8U ,

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Antiproliferative capabilities of rutin, benzoic acid (BA) and triazolofluoroqunolone (TFQ) derivatives were reported; hence chemosensitizing effects of rutin or its polymeric micelles (of improved solubility and bioavailability via direct dissolution using the amphiphilic copolymer Pluronic P123) in co-incubations with 5 BAs or 3 TFQ derivatives in a panel of 6 cancer cell lines were verified."( Preparation and Characterization of Rutin-Encapsulated Polymeric Micelles and Studies of Synergism with Bioactive Benzoic Acids and Triazolofluoroquinolones as Anticancer Nanomedicines.
Alhiari, Y; Alkhateeb, R; Ibrahim, R; Kasabri, V; Shalabi, D; Sunoqrot, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
reagentA substance used in a chemical reaction to detect, measure, examine, or produce other substances.
genotoxinA role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
substituted aniline
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency56.23410.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency83.48910.007215.758889.3584AID1224835
GLI family zinc finger 3Homo sapiens (human)Potency32.24280.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency54.69470.000221.22318,912.5098AID743035; AID743054; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency64.06390.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency48.16300.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.19310.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency54.49760.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency12.34840.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency52.99370.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.22890.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.28750.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.20430.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency53.26140.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency60.63360.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.10780.001628.015177.1139AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency29.36450.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency79.36040.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency66.25720.000323.4451159.6830AID743065; AID743067
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.00630.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.93720.000627.21521,122.0200AID651741; AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID23978Capacity ratio (log k'w)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID203473Binding constant against bovine serum albumin1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID23714Partition coefficient (logP)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID158694In vitro inhibitory concentration against chloroquine-resistant Plasmodium falciparum; Not active2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Evidences for the formation of bisbenzamidine-heme complexes in cell-free systems.
AID1145375Antimicrobial activity against Mycobacterium tuberculosis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID619509Dissociation constant, pKa of the compound in aqueous solution2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Aryl H-phosphonates 17: (N-aryl)phosphoramidates of pyrimidine nucleoside analogues and their synthesis, selected properties, and anti-HIV activity.
AID158696In vitro inhibitory concentration against chloroquine-sensitive Plasmodium falciparum; Not active2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Evidences for the formation of bisbenzamidine-heme complexes in cell-free systems.
AID26081pKa was determined1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (10.96)18.7374
1990's3 (4.11)18.2507
2000's12 (16.44)29.6817
2010's40 (54.79)24.3611
2020's10 (13.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.17 (24.57)
Research Supply Index4.33 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index25.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (1.33%)4.05%
Observational0 (0.00%)0.25%
Other74 (98.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]